Acasă › Cancer pulmonar cu celule non-pătrate › Kentucky › Louisville
Studii clinice pentru Cancer pulmonar cu celule non-pătrate în Louisville, KY
22 studii pentru Cancer pulmonar cu celule non-pătrate caută participanți în și în jurul orașului Louisville (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Study of ZW251 in Participants With Advanced Solid Tumors
În curs de recrutareFaza 1
- Norton Cancer Institute, Louisville
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
În curs de recrutareFaza 1/2
- James Graham Brown Cancer Center (Melanoma/NSCLC), Louisville
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
În curs de recrutareFaza 3
- Baptist Health Louisville, Louisville
- Baptist Health Floyd, New Albany · La 4 mi distanță
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
În curs de recrutareFaza 3
- Norton Cancer Institute Downtown, Louisville
- Norton Cancer Institute, Downtown, Louisville
- Norton Hospital, Louisville
- și încă 4
Pan-tumor MRD Study
În curs de recrutareStudiu observațional
- Baptist Health Louisville, Louisville
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
În curs de recrutareFaza 3
- The University of Louisville, James Graham Brown Cancer Center, Louisville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
În curs de recrutareFaza 1
- Norton Cancer Institute, Louisville
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
În curs de recrutareFaza 3
- Research Site, Louisville
- Research Site, Louisville
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
În curs de recrutareFaza 2/3
- University of Louisville, Louisville
- Local Institution - 007-388-A, Louisville
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
În curs de recrutareFaza 1/2
- Norton Cancer Institute Research, Louisville
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
În curs de recrutareFaza 1/2
- Norton Cancer Institute PARENT, Louisville
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
În curs de recrutareFaza 3
- Research Site, Louisville
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
În curs de recrutareFaza 1/2
- Norton Cancer Institute, Louisville
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
În curs de recrutareFaza 1
- Norton Cancer Institute, Louisville
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
În curs de recrutareFaza 2
- University of Louisville, Louisville
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
În curs de recrutareFaza 1
- Norton Cancer Institute /ID# 248903, Louisville
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
În curs de recrutareFaza 1/2
- University of Louisville, Louisville
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
În curs de recrutareFaza 3
- Research Site, Louisville
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 2
- University Medical Center, lnc.:DBA University of Louisville Hospital, Louisville
- University of Louisville, Louisville
- UofL Health Brown Cancer Center, Louisville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
În curs de recrutareFaza 1/2
- Research Site 115, Louisville
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
În curs de recrutareFaza 1
- Research Site, Louisville
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
În curs de recrutare
- James Graham Brown Cancer Center, Louisville
Studii pentru Cancer pulmonar cu celule non-pătrate în alte orașe
- Houston, TX145 studii
- New York City, NY121 studii
- Arlington, VA104 studii
- Nashville, TN97 studii
- Boston, MA90 studii
- Los Angeles, CA87 studii
- St. Louis, MO73 studii
- Chicago, IL61 studii
- Baltimore, MD60 studii
- San Antonio, TX59 studii
- Columbus, OH57 studii
- Washington, DC55 studii
Alte studii în Louisville
- Obezitate17 studii
- Supraponderalitate15 studii
- Cancer (toate tipurile)14 studii
- Insuficiență cardiacă13 studii
- Leucemie mieloasă acută12 studii
- Mielom multiplu12 studii
- Cancer ovarian12 studii
- Cancer de sân11 studii
- Carcinom cu celule scuamoase de cap și gât11 studii
- Cancer pulmonar11 studii
- Melanom10 studii
- Cancer de prostată10 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.